Metagenomi, INC Form 4 insider transactions

Metagenomi, Inc.'s President and Chief Operating Officer, Jian Irish, sold 6,390 shares of common stock at $1.75 per share on June 6, 2025, solely to satisfy tax withholding obligations related to restricted stock unit vesting.

Pamela Wapnick, CFO of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Metagenomi's CEO, Brian C. Thomas, reports acquisition of 32,000 shares of common stock and 196,000 stock options.

Jian Irish, President and COO of Metagenomi, reports acquisition of restricted stock units and stock options, along with indirect holdings through trusts.

Matthew Wein, a Metagenomi executive, reported the acquisition of restricted stock units and stock options in a recent SEC filing.

Sarah Noonberg, Chief Medical Officer of Metagenomi, Inc., reports the acquisition of restricted stock units and stock options.

Matthew Wein, a Metagenomi executive, sold 930 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Pamela Wapnick, CFO of Metagenomi, Inc., sold 1,808 shares of common stock on March 5, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Director Eric Bjerkhot of Metagenomi, Inc. (MGX) acquired stock options for 42,000 shares at an exercise price of $2.51 on February 3, 2025.

Metagenomi's Chief Financial Officer, Pamela Wapnick, sold 1,559 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pamela Wapnick, CFO of Metagenomi, Inc., sold 6,265 shares of common stock on September 5, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Jian Irish, President and COO of Metagenomi, reports the acquisition of restricted stock units and stock options.

Juergen Eckhardt, a director of Metagenomi, Inc. (MGX), acquired stock options for 78,636 shares on April 1, 2024.

Luis Borges, Chief Scientific Officer of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units.

Matthew Wein, Vice President of Corporate Legal and Compliance, and Corporate Secretary at Metagenomi, reported the acquisition of restricted stock units and stock options.

Pamela Wapnick, CFO of Metagenomi, Inc., reports the acquisition of stock options and restricted stock units.

Chief Medical Officer of Metagenomi, Sarah B. Noonberg, reports acquisition of restricted stock units and stock options.

Director Sebastian Bernales acquired stock options for 78,636 shares of Metagenomi, Inc. on April 1, 2024.

Simon Harnest, Chief Investment Officer and Senior Vice President of Strategy at Metagenomi, recently acquired shares and options in the company, as detailed in a Form 4 filing.

Simren Delaney, a Vice President at Metagenomi, reported the acquisition of restricted stock units and stock options.

Director Willard H Dere acquired 78,636 stock options in Metagenomi, Inc. on April 1, 2024, according to a Form 4 filing with the SEC.

Brian C. Thomas, CEO of Metagenomi, Inc., reports acquisition of common stock and stock options.